These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17680975)

  • 1. Imatinib-induced erythroderma.
    Mathew T; Chandrashekar L; Pulimood S; Srivastava A
    Australas J Dermatol; 2007 Aug; 48(3):193-4. PubMed ID: 17680975
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
    Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
    Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib mesylate induced erythroderma.
    Sanghavi SA; Dongre AM; Khopkar US
    Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
    [No Abstract]   [Full Text] [Related]  

  • 5. Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
    Jørgensen HG; Copland M; Holyoake TL
    Cancer; 2005 Jan; 103(1):210-11. PubMed ID: 15540243
    [No Abstract]   [Full Text] [Related]  

  • 6. A rare case of imatinib-induced erythroderma.
    Verma R; Vasudevan B; Pragasam V; Neema S
    Indian J Pharmacol; 2013; 45(6):634-5. PubMed ID: 24347779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible hair depigmentation in a patient treated with imatinib.
    Mariani S; Abruzzese E; Basciani S; Fiore D; Persichetti A; Watanabe M; Spera G; Gnessi L
    Leuk Res; 2011 Jun; 35(6):e64-6. PubMed ID: 21176848
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
    Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
    Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.
    Kawakami T; Kawanabe T; Soma Y
    Acta Derm Venereol; 2009; 89(3):325-6. PubMed ID: 19479144
    [No Abstract]   [Full Text] [Related]  

  • 10. Loss of skin pigment caused by imatinib therapy.
    McPartlin S; Leach M
    Br J Haematol; 2005 May; 129(4):448. PubMed ID: 15877727
    [No Abstract]   [Full Text] [Related]  

  • 11. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib.
    Ugurel S; Lahaye T; Hildenbrand R; Glorer E; Reiter A; Hochhaus A; Schadendorf D; Goerdt S
    Br J Dermatol; 2003 Sep; 149(3):678-9. PubMed ID: 14511021
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
    Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
    Woo SM; Huh CH; Park KC; Youn SW
    J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
    [No Abstract]   [Full Text] [Related]  

  • 15. Generic imatinib: the real-deal or just a deal?
    Mathews V
    Leuk Lymphoma; 2014 Dec; 55(12):2678-80. PubMed ID: 24798742
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
    Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
    Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
    Franceschino A; Tornaghi L; Benemacher V; Assouline S; Gambacorti-Passerini C
    Haematologica; 2008 Feb; 93(2):317-8. PubMed ID: 18245661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
    Chang H; Shih LY
    Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
    Mcpherson T; Sherman V; Turner R
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.